Frank Au is the co-founder and Managing Partner of PacificPine, a technology growth capital firm. Mr Au has spent over 20 years covering the technology and healthcare market in China. Mr Au has spent over 15 years as an entrepreneur having founded, built and sold an independent investment banking business.
Mr Au is the former President of China Renaissance Securities (HK), the wholly-owned broker dealer subsidiary of China Renaissance Group, the largest Internet sector focused full service investment bank in China. Prior to China Renaissance, Mr Au was the former CEO of Cowen and Company Asia and a member of Cowen’s global management committee. Prior to Cowen, Mr Au was the co-founder and President of Latitude Capital Group, a boutique M&A and private placement advisory firm with offices in Hong Kong, Beijing and Shanghai which was acquired by Cowen Group (COWN:US). Prior to co-founding Latitude, Mr Au was the former Head of Internet investment banking for Greater China at Lehman Brothers Asia. Mr Au worked for Lehman Brothers in both their New York and Hong Kong offices and served stints in the Firm’s TMT, LBO and Industrial investment banking coverage groups.
Mr Au holds a MBA from Harvard Business School and a BA from Columbia University.
Prof Oppel Greef holds a Bachelors degree in Medicine and Surgery MBChB (Pret); Post graduate qualifications in Primary Health Care, FCFP (SA); MPharmMed (Pret); Pharmaceutical Medicine FFPM (Royal Colleges of Physicians (UK)) and a MD (Psychiatry) (KZN).
In 1990 he founded Clindepharm International, the first Contract Research Organization in South Africa, which he sold to Quintiles Transnational Corporation in August 1997 and continued his employment at Quintiles.
In 2002 he was appointed CEO of Early Development & Laboratory Services worldwide for Quintiles in the USA and in the same year as President: Global Product Development Services(PDS), and was appointed on the Executive Committee of Quintiles.
Oppel chaired the Asia-Pacific Management Board of Quintiles TRN from 2005 – 2013 and was Chairman of the Quintiles-Fisher JV, Cenduit, an ITS enterprise in 2007.
In August, 2008 Prof Greeff was appointed professor and head of the department of Pharmacology, School of Medicine, Faculty of Health Sciences at the University of Pretoria and relocated back to South-Africa.
Dr. Declan Doogan received his Medical degree from Glasgow University in 1975 and joined Pfizer in 1982, where he was in charge of the sertraline(R) (Zoloft) clinical development program. He has held a number of senior positions in research and development in Pfizer in the United States, United Kingdom, and Japan.Heretired from Pfizer in 2007 as the Head of Worldwide Development.
Dr. Doogan is on the Board of the not-for-profit, Pulmonary Vascular Research Institute. Doogan has held Visiting Professorships at Harvard School of Public Health, Glasgow University Medical School, and Kitasato University (Tokyo) and is Adjunct Professor of Psychiatry at the University of Cork . He is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine in the United Kingdom and received a Doctorate of Science from the University of Kent.